Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Edetate Calcium Disodium Coverage | OpenPaye…
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0138

    Chelating Agent - Edetate Calcium Disodium

    Customize your policy alerts

    Sign up for Cigna Policy IP0138 alerts

    Get alerted when Policy IP0138 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for edetate calcium disodium for medically necessary treatment of acute or chronic lead poisoning, including lead encephalopathy, subject to indication and dosing criteria.

    Policy Summary
    PayerCigna
    PolicyChelating Agent - Edetate Calcium Disodium
    Policy CodePolicy IP0138
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and confirm that the covered lead-poisoning indication and dosing criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    The policy title was updated from “Dimercaprol and Edetate Calcium Disodium” to “Chelating Agent - Edetate Calcium Disodium.”

    BAL in Oil (dimercaprol) was removed from the coverage policy.

    The blood lead level criterion requiring a level greater than 44 mcg/dL was removed from the coverage requirements.

    1Covered indication
    5 daysInitial course
    2-4 daysSecond course interval
    4 weeks

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Additional course interval
    4Noncovered uses
    J0600Covered HCPCS code

    Medical Necessity and Noncovered Uses

    Medically Necessary Lead Poisoning Treatment

    Edetate Calcium Disodium (Calcium EDTA; Calcium Disodium Versenate) is considered medically necessary when ALL of the following criteria are met:

    ALL of the following

    • The indication is acute or chronic lead poisoning, including lead encephalopathy.

      Approve for 1 month.

    • Both dosing requirements

      • The dose is up to 1000 mg/m²/day for 5 days, followed by a second 5-day course given 2 to 4 days later if indicated.
      • If additional courses are needed, courses are given no more frequently than every 4 weeks.

    Services for or in connection with an injury or illness arising out of, or in the course of, any employment for wage or profit are explicitly excluded under most Cigna benefit plans. Therefore, treatment of metal toxicity that occurs as a result of occupational exposure is generally not covered.

    Treatment of mercury toxicity attributed to dental amalgam fillings is not covered. FDA issued updated dental amalgam recommendations in 2020, recommending that certain high-risk groups avoid new dental amalgam when possible and appropriate. However, FDA also stated that it does not recommend removal or replacement of existing amalgam fillings in good condition unless medically necessary, because removal may temporarily increase mercury vapor exposure and may result in loss of healthy tooth structure. FDA's 2020 dental amalgam communication does not establish edetate calcium disodium as treatment for alleged mercury toxicity from dental amalgam fillings.

    Treatment of poisoning caused by other heavy metals, including aluminum, arsenic, cadmium, cobalt, manganese, mercury, plutonium, or uranium toxicity, is not covered when the condition is not otherwise addressed in the Medically Necessary criteria. Treatment is not clinically supported.

    Edetate Calcium Disodium for atherosclerotic vascular disease is not medically necessary. Chelation therapy with ethylene diamine tetra-acetic acid (EDTA) has been proposed for atherosclerotic cardiovascular disease; however, evidence remains insufficient to support routine use. A 2022 systematic review, Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review, searched MEDLINE, Embase, and Cochrane through October 2021 and identified 24 studies, including four randomized clinical trials. The authors reported mixed findings, with differences across infusion regimens and study designs limiting interpretation, and concluded that additional research was needed. TACT2, a randomized clinical trial in patients with diabetes and prior myocardial infarction, found that EDTA-based chelation reduced median blood lead levels but did not reduce major adverse cardiovascular events compared with placebo. The primary composite outcome occurred in 35.6% of the chelation group and 35.7% of the placebo group, with adjusted HR 0.93, 95% CI 0.76 to 1.16, and p=0.53.

    Edetate Calcium Disodium for autism spectrum disorders is not medically necessary. Chelation has been proposed based on the theory that removal of heavy metals may improve symptoms; however, a Cochrane review found no clinical trial evidence that pharmaceutical chelation is an effective intervention for autism spectrum disorder symptoms. The review also noted prior serious adverse events, including hypocalcemia, renal impairment, and reported death, and concluded that risks currently outweigh proven benefits. The proposal is based on the theory that the chelating agent will remove mercury thought to be contained in tissue after early childhood vaccinations in children with autism spectrum disorder. Several studies have examined the relationship of mercury to autism spectrum disorder, but no consistent associations have been identified. There is insufficient evidence in the peer-reviewed literature regarding the efficacy of chelation therapy for treatment of autism spectrum disorder.

    Edetate Calcium Disodium for treatment of mercury toxicity attributed to dental amalgam fillings is not medically necessary. FDA's 2020 dental amalgam communication does not establish edetate calcium disodium as treatment for alleged mercury toxicity from dental amalgam fillings.

    Edetate Calcium Disodium for heavy-metal poisoning or toxicity not otherwise addressed in the Medically Necessary criteria is not medically necessary. Treatment of poisoning caused by other heavy metals, including aluminum, arsenic, cadmium, cobalt, manganese, mercury, plutonium, or uranium toxicity, is not clinically supported. This list may not be all inclusive; criteria will be updated as new published data are available.

    Codes and Dosing Reference

    Considered Medically Necessary HCPCS CodeHCPCSCovered
    J0600Injection, edetate calcium disodium, up to 1,000 mg
    Blood lead level for standard dosing
    Standard dose1,000 mg/m²/day
    Applies toAsymptomatic patients with blood lead < 70 mcg/dL
    Use BAL with edetate calcium disodiumWhen blood lead is > 70 mcg/dL or when clinical symptoms or encephalopathy are present
    Renal impairment: serum creatinine 2-3 mg/dL
    Serum creatinine2-3 mg/dL
    Dose500 mg/m²
    Frequency and duration

    Authorization and Coverage Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of edetate calcium disodium. Approval is recommended only when the request meets the policy’s covered-indication criteria and dosing requirements.

    Denial Risk

    Noncovered Indications

    Edetate calcium disodium for uses outside the covered acute or chronic lead-poisoning indications is considered not medically necessary and will not be covered. This includes atherosclerotic vascular disease, autism spectrum disorders, and other indications not supported by sufficient clinical evidence.

    • Chelation for atherosclerotic vascular disease is not supported by sufficient evidence of improved cardiovascular outcomes.
    • Chelation for autism spectrum disorders lacks evidence of efficacy and carries serious potential risks, including hypocalcemia and renal impairment.

    Clinical Background

    Edetate calcium disodium is a chelating agent indicated to reduce blood lead levels and depot stores in acute or chronic lead poisoning, including lead encephalopathy, in pediatric and adult patients. Chelation does not replace measures to eliminate or reduce continued lead exposure. Because the drug can cause serious or fatal toxicity, prescribed dosage limits and monitoring of renal function, hepatic function, and urine output are important.

    Policy Terms

    Edetate calcium disodium
    Policy drugEdetate calcium disodium
    AliasCalcium Disodium Versenate
    Other nameCalcium EDTA
    BAL
    Full nameDimercaprol
    DefinitionBAL is the abbreviation for dimercaprol
    Combination useUse with edetate calcium disodium when blood lead is > 70 mcg/dL or when clinical symptoms or encephalopathy are present

    Initial Lead Poisoning Therapy

    Initial Treatment of Lead Poisoning

    Approve when the patient has the covered lead-poisoning indication and dosing meets both requirements.

    Initial therapy

    • Covered indication

      • The patient has acute lead poisoning.
      • The patient has chronic lead poisoning.
      • The patient has lead encephalopathy.
    • Dosing requirements

      • Administer up to 1000 mg/m² per day for 5 days, followed by a second 5-day course given 2 to 4 days later if indicated.

    Repeat Treatment Courses

    Repeat-Course Requirement

    If additional courses are needed, they must be administered no more frequently than every 4 weeks.

    Additional courses: Any additional course must be separated from the preceding course by at least 4 weeks.No more frequently than every 4 weeks

    Dosing and Course Limits

    Quantity limit
    DrugEdetate calcium disodium
    Approval limitApprove for 1 month
    Covered indicationAcute or chronic lead poisoning, including lead encephalopathy
    Course dosing
    Daily doseUp to 1000 mg/m²/day
    Initial course5 days
    Second courseA second 5-day course may be given 2 to 4 days later if indicated
    Policy Summary
    PayerCigna
    PolicyChelating Agent - Edetate Calcium Disodium
    Policy CodePolicy IP0138
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and confirm that the covered lead-poisoning indication and dosing criteria are met.
    SourceLink
    On This Page
    Medical Necessity and Noncovered UsesCodes and Dosing ReferenceAuthorization and Coverage RisksClinical BackgroundPolicy TermsInitial Lead Poisoning TherapyRepeat Treatment CoursesDosing and Course Limits
    Every 24 hours for 5 days
    Renal impairment: serum creatinine 3-4 mg/dL
    Serum creatinine3-4 mg/dL
    FrequencyEvery 48 hours
    Number of doses3 doses
    Renal impairment: serum creatinine > 4 mg/dL
    Serum creatinine> 4 mg/dL
    FrequencyOnce weekly
    AdjustmentUse an extended dosing interval for renal impairment
    Denial Risk

    Occupational Exposure Generally Excluded

    Treatment of metal toxicity arising from occupational exposure is generally not covered because services for injuries or illnesses arising out of employment are explicitly excluded under most Cigna benefit plans.

    • Assess whether the exposure occurred in the course of employment for wage or profit.
    • Coverage may depend on the member’s specific benefit plan.
    Prior Authorization

    Out-of-Policy Dosing

    Requests for dosing outside the established policy regimen require case-by-case review by a clinician, such as a Medical Director or Pharmacist, and may not be approved.

    • Standard dosing: up to 1000 mg/m²/day for 5 days, followed by a second 5-day course 2 to 4 days later if indicated.
    • Additional courses must be administered no more frequently than every 4 weeks.
    Denial Risk

    Dental Amalgam-Attributed Mercury Toxicity

    Edetate calcium disodium is not medically necessary for mercury toxicity attributed to dental amalgam fillings. FDA recommendations regarding dental amalgam do not establish edetate calcium disodium as treatment for alleged mercury toxicity, and removal of intact amalgam may increase mercury vapor exposure and damage healthy tooth structure.

    • Do not submit edetate calcium disodium requests for alleged dental-amalgam-related mercury toxicity as a covered medically necessary indication.
    • FDA does not recommend removing or replacing existing amalgam fillings in good condition unless medically necessary.
    Denial Risk

    Unaddressed Heavy-Metal Toxicity

    Treatment of heavy-metal poisoning or toxicity not otherwise addressed in the policy’s medically necessary criteria is not clinically supported and is considered not medically necessary.

    • Noncovered examples include aluminum, arsenic, cadmium, cobalt, manganese, mercury, plutonium, and uranium toxicity.
    • Requests must meet the policy’s specified medically necessary indication criteria.
    Up to 1000 mg/m²/day for 5 days; second 5-day course 2–4 days later if indicated
  1. If additional courses are needed, administer courses no more frequently than every 4 weeks.No more frequently than every 4 weeks